← Russell 3000 cross-section

MGNX MACROGENICS INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-14, not restated
Healthcare

Scale

Market cap
$261m
Revenue TTM
$168m
Net income TTM
$-15m
Free cash flow
$-66m
Composite score
Sector rank
#2749

Valuation

P / E
EV / EBITDA
EV / sales
0.9
FCF yield
-25.13%
Earnings yield vs 10-yr
-10.33pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-8.7%
EBITDA margin
-20.8%
ROE
-34.0%
ROIC
Revenue growth
1.3%

Insider activity, last 90 days

Net open-market
$-0.13m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings and revenue from its multiple collaboration agreements. Reclassification Royalty revenue of approximately $ 1.3 million and $ 1.8 million for the three and six months ended June 30, 2025, respectively, was reclassified from Collaborative and other agreements to Royalty revenue on the consolidated statement of operations and comprehensive income (loss) to conform to the current period presentation. 2. …MACROGENICS INC, 10-Q, period ended 2026-06-30, filed 2026-08-14

Read the full passage →